Digital cognitive-behavioural therapy application compared with zolpidem for the treatment of insomnia: protocol for an exploratory randomised controlled trial

Shimizu,E.,Sato,D.,Hirano,Y.,Ebisu,H.,Kagayama,Y.,Hanaoka,H.
DOI: https://doi.org/10.1136/bmjopen-2023-081205
IF: 3.006
2024-06-26
BMJ Open
Abstract:Introduction Insomnia is a common health problem and cognitive–behavioural therapy (CBT) is recommended as a treatment. As there is a critical shortage of CBT-trained therapists, we developed a digital CBT application (IIIP MED: Sleepy Med) as Software as a Medical Device for insomnia. This paper describes the study protocol for an exploratory randomised controlled trial (RCT) to evaluate effectiveness and safety of our developed digital CBT (dCBT) for 5 weeks compared with zolpidem tartrate for patients with insomnia disorder. Methods and analysis This proposed multicentre exploratory RCT will be conducted at the outpatient clinic of Chiba University Hospital, Akita University Hospital and Yoyogi Sleep Disorder Center, Japan. The study population comprises two parallel groups (dCBT and zolpidem) consisting of 15 participants each (n=30 in total) diagnosed with insomnia disorder who remain symptomatic at 4 weeks after sleep hygiene education. We will evaluate the effectiveness at baseline, week 5 (post-intervention) and week 10 (follow-up). The primary outcome will be the change of subjective sleep onset latency at week 5 from baseline. Secondary outcomes include sleep-related outcomes, such as objective sleep onset latency measured by mobile electroencephalography, functional improvement during the daytime and quality of life. Ethics and dissemination Ethics approval was granted by the Institutional Review Board of Chiba University Hospital (K2023001). All participants will be required to provide written informed consent. Results will be published in international journals. Trial registration number jRCT2032230353.
medicine, general & internal
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to evaluate the effectiveness and safety of a new digital cognitive - behavioral therapy (dCBT) application and zolpidem in treating patients with insomnia. Specifically, the study aims to compare the treatment effects of a 5 - week digital cognitive - behavioral therapy application (IIIP MED: Sleepy Med) with zolpidem on patients with insomnia through an exploratory randomized controlled trial (RCT). ### Research Background - **Insomnia**: Insomnia is a common health problem, manifested as difficulty in falling asleep or frequent waking up at night, leading to a decline in daytime function. According to the third edition of the International Classification of Sleep Disorders, chronic insomnia is defined as having nocturnal sleep disorders and related daytime impairments at least three nights a week for more than 3 months. - **Cognitive - behavioral therapy for insomnia (CBT - I)**: CBT - I is recommended as the first - choice treatment method for chronic insomnia. However, due to the lack of trained CBT - I therapists, this therapy is not easily accessible worldwide. - **Digital cognitive - behavioral therapy (dCBT)**: In order to overcome the limitations of traditional CBT - I, researchers have developed a digital cognitive - behavioral therapy application (IIIP MED: Sleepy Med) as a software as a medical device (SaMD) for treating insomnia. ### Research Objectives - **Primary objective**: To evaluate the effectiveness and safety of a 5 - week digital cognitive - behavioral therapy application (IIIP MED: Sleepy Med) and zolpidem in treating patients with insomnia. - **Secondary objective**: To evaluate other sleep - related indicators, such as objective sleep latency (measured by mobile electroencephalogram), improvement of daytime function and quality of life. ### Research Design - **Research type**: Multicenter exploratory randomized controlled trial (RCT). - **Research sites**: Outpatient departments of Chiba University Hospital, Akita University Hospital and Yoyogi Sleep Disorder Center in Japan. - **Research subjects**: 30 adult patients with insomnia, divided into two groups (15 in each group), who still had symptoms after 4 weeks of sleep hygiene education. - **Interventions**: - **dCBT group**: Use the digital cognitive - behavioral therapy application (IIIP MED: Sleepy Med) for 5 - week treatment. - **Zolpidem group**: Take 5 mg of zolpidem every day before going to bed for 5 weeks. - **Assessment time points**: Baseline (day 1), post - intervention (week 5, day 36) and follow - up (week 10, day 71). ### Main Results - **Primary result**: The change in subjective sleep latency at week 5 (based on the participants' 7 - day consecutive paper - based sleep diaries). - **Secondary results**: Include sleep - related indicators (such as objective sleep latency measured by mobile electroencephalogram), improvement of daytime function and quality of life, etc. ### Research Significance - **Innovation**: This study provides a new and easily accessible method for treating insomnia, especially for those patients who cannot obtain traditional CBT - I treatment. - **Practicality**: By comparing the effects of dCBT and zolpidem, more treatment options can be provided for clinicians and the risk of long - term use of sleeping pills may be reduced. Hope this information can help you better understand the purpose and content of this study. If you have any further questions, feel free to ask!